Competing interests
S.M.M. has received consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daichii-Sankyo, Eli Lilly, esanum, Gilead, Ipsen, Novartis, Novo Nordisk, Sandoz and Sanofi, and has received research grants from AstraZeneca, Eli Lilly and Novo Nordisk. B.C. has received consulting honoraria from Abbott, Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Novartis, Novo Nordisk, Sanofi and Ultragenyx, and research funding to his institution from Air Liquide, Sanofi and Ypsomed. C.C. has received consulting honoraria from Brace Pharma, Eli Lilly, Eurofarma, Merck and Novo Nordisk. H.M.C. has served on advisory panels for Bayer and Novo Nordisk, has received research funding from IQVIA, Roche and Sanofi, has received grants from the Chief Scientist Office, Diabetes UK, the European Commission, the Juvenile Diabetes Research Foundation and the Medical Research Council, has served on a speaker’s bureau for Novo Nordisk and holds stock in Bayer and Roche Pharmaceuticals. J.D. has received consulting honoraria from Aegerion, Amgen, Bayer, Boehringer Ingelheim, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi and Takeda, and research grants from Aegerion, the British Heart Foundation, Colgate, the Medical Research Council (UK), Merck Sharp & Dohme, the National Institute for Health and Care Research, Pfizer, Public Health England and Roche. M.T.L., O.K.J. and M.Q. are employees of Novo Nordisk. A.M.L. has received research grants from AbbVie, AstraZeneca, CSL Behring, Eli Lilly, Esperion Therapeutics and Novartis, paid to his institution, and has served as a consultant for Akebia Therapeutics, Alnylam Pharmaceuticals, Ardelyx, Canary Cure, Eli Lilly, FibroGen, GlaxoSmithKline, Intarcia, Medtronic Vascular, the Novartis Pharmaceuticals Corporation, Novo Nordisk, Provention Bio, and ReCor Medical. I.L. has received research grants from Boehringer Ingelheim, Merck, Mylan Pharmaceuticals, Novo Nordisk, Pfizer and Sanofi US Services, has served as a consultant for AstraZeneca, Bayer Healthcare Pharmaceuticals, Biomea, Boehringer Ingelheim, Carmot, Eli Lilly, Intarcia, Intercept Pharmaceuticals, Janssen Global Services, Johnson & Johnson Medical Devices & Diagnostics Group-Latin America, MannKind Corporation, Merck, Novo Nordisk, Pfizer, Sanofi US Services, Shionogi, StructureTherapeutics, Target Pharma, Valeritas and Zealand Pharma, and has received travel expenses from Boehringer Ingelheim, Eli Lilly, Johnson & Johnson Medical Devices & Diagnostics Group-Latin America, Novo Nordisk, Sanofi US Services and Zealand Pharma. J.P. has received consulting honoraria from Altimmune, Amgen, Esperion Therapeutics, Merck, MJH Life Sciences, Novartis and Novo Nordisk, has received a grant, paid to his institution, from Boehringer Ingelheim and holds the position of Director, Preventive Cardiology at Brigham and Women’s Hospital. P.N.N. has received consulting fees from Aligos, Boehringer Ingelheim, Madrigal, Novo Nordisk, Sagimet, Shionogi and 89bio. S.J.N. has received research support from Amgen, Anthera, AstraZeneca, Cerenis, CSL Behring, Cyclarity, Eli Lilly, Esperion, Infraredx, New Amsterdam Pharma, Novartis, Resverlogix and Sanofi-Regeneron, and is a consultant for Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, CSL Sequiris, Eli Lilly, Esperion, Kowa, Merck, Novo Nordisk, Pfizer, Sanofi-Regeneron, Takeda and Vaxxinity. F.S. has worked as a consultant for, participated in studies for or received travel funds from the following companies that are involved with obesity, lipodystrophy or diabetes: Aegerion/Amryt, BioItalia, Boehringer Ingelheim, Bruno Pharma, Lilly, Novo Nordisk and Pfizer. A.J.S. consults for and advises AstraZeneca and Avant Santé, consults for and has received grants from Akero, Bristol Myers Squibb, Eli Lilly, Intercept, Madrigal and Novo Nordisk, consults for and owns stock in Rivus, consults for 89bio, AGED Diagnostics, Albireo, Alnylam, Altimmune, Boehringer Ingelheim, Echosens, Genentech, Gilead, GlaxoSmithKline, HistoIndex, Mallinckrodt, Merck, NGM Bio, Novartis, PathAI, Pfizer, Poxel, Regeneron, Salix, Siemens, Surrozen, Takeda, Terns and Zydus, owns stock in Durect, Exalenz, Genfit, Indalo, Inversago and Tiziana, and has received royalties from Elsevier and Wolters Kluwer. S.E.K. has received consulting honoraria from Anii Pharmaceuticals, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk and Oramed, and stock options from Altpep.
